Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf G, English J, Kirschmeier PT, Velculescu VE, Paweletz CP, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R.: Establishment of patient - derived
tumor xenograft models of
epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics.
A class of drugs called EZH2 inhibitors are currently in clinical development for both hematological malignancies and solid
tumors and may be effectively targeted to
epithelial ovarian cancers overexpressing the CARM1 protein.